Gelonghui, April 25 | Ligao Health Life (02370.HK) announced that the stable price period for the global sale ended on April 24, 2022 (that is, the 30th day after the deadline for submitting Hong Kong public sale applications). Since there are no overallotments of shares offered internationally, the sole representative (for himself or for the underwriter) will not exercise overallotment rights and the price stabilizer or anyone acting for it will not perform any price stabilization action relating to the global offering during the price stabilization period. Over-allotment rights expire on April 24 (that is, the 30th day after the deadline for submission of applications for the Hong Kong public offering). As a result, no shares have been issued or will be issued on the basis of over-allotment rights.